Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody

Rheumatology International

Volumn 33, Issue 6, 2013, Pages 1443-1446

  Ryu, Yang Seon ^a   Park, Sung Hwan ^b   Lee, Jennifer ^b   Kwok, Seung Ki ^b   Ju, Ji Hyeon ^b   Kim, Ho Youn ^b   Jeon, Chan Hong ^a  

^a Soonchunhyang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anti CCP antibody; Primary Sjogren's syndrome; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME;

EID: 84878744987     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2572-4     Document Type: Article

References (15)

1. Maejima H, Aki R, Watarai A et al (2010) Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol 37:339-345
2. Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163
3. van Jaarsveld CH, ter Borg EJ, Jacobs JW et al (1999) The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689-697
4. Visser H, le Cessie S, Vos K et al (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357-365
5. Bloch KJ, Buchanan WW, Wohl MJ et al (1965) Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 44:187-231
6. Castro-Poltronieri A, Alarcon-Segovia D (1983) Articular manifestations of primary Sjogren's syndrome. J Rheumatol 10:485-488
7. Fox RI, Stern M, Michelson P (2000) Update in sjogren syndrome. Curr Opin Rheumatol 12:391-398
8. Atzeni F, Sarzi-Puttini P, Lama N et al (2008) Anti-cyclic citrullinated peptide antibodies in primary sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 10:R51
9. Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273-281
10. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709-715
11. Bjerrum K, Prause JU (1990) Primary Sjogren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 8:283-288
12. Fauchais AL, Ouattara B, Gondran G et al (2010) Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 49:1164-1172
13. Sanders S, Harisdangkul V (2002) Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 323:190-193
14. Skopouli FN, Jagiello P, Tsifetaki N et al (1996) Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 14:555-558
15. Royer B, Cazals-Hatem D, Sibilia J et al (1997) Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90:766-775